We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Data Integrity, Biosimilars, Generics Top Priorities for 2016 FDA Guidances
Data Integrity, Biosimilars, Generics Top Priorities for 2016 FDA Guidances
The FDA has updated its list of scheduled guidances for the calendar year 2016, with a major focus on pharmaceutical quality, data integrity and generics. There are 102 planned guidances this year, compared with 92 last year.